Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 27;30(17):3715–3725. doi: 10.1158/1078-0432.CCR-23-3874

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2024 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

PMC Copyright notice

Figure 1. — A, Trial outline. B, Lymphocyte changes after TILT-123, all cohorts pooled. C, Leukocyte changes after TILT-123, all cohorts pooled. D, Neutrophil changes after TILT-123, all cohorts pooled. E, Virus detection in blood by qPCR, before treatment, 1 hour post-treatment and 16 hours post-treatment, all dose cohorts available pooled (N = 10 patients). F, Virus detection in blood by qPCR 1 hour after intravenous dose, stratified by intravenous dose given. G, Virus detection in blood by qPCR 1 hour after intratumoral dose, stratified by intratumoral dose given. For all graphs, mean ± SEM shown. For B–D, P value from two-sided t test shown for graphs. LLOQ, lower limit of quantification; ns, non-significant (P > 0.05); *, P < 0.05; ****, P < 0.001.